Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-05-28

Clinical Trial Update: Bioequivalence of Ethylenediamine Dihydrochloride Study [Phase 4]

View source ↗

Summary

A Phase 4 trial update reports bioequivalence testing for Ethylenediamine Dihydrochloride in Allergic Contact Dermatitis; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ethylenediamine dihydrochloride (ethylenediamine dihydrochloride)

Snippet

Sponsor: Allerderm | Conditions: Allergic Contact Dermatitis | Phase 4 | Status: COMPLETED | Results posted: 2020-05-28